Hypotension from ganglionic blockade is a side effect produced by which neuromuscular blockers?

Hypotension from ganglionic blockade is primarily associated with D-tubocurarine and Metocurine. These neuromuscular blockers can cause a reduction in blood pressure due to their action at the neuromuscular junction, which can inadvertently affect autonomic ganglia and lead to ganglionic blockade. When ganglionic transmission is interrupted, the sympathetic tone is reduced, resulting in vasodilation and a subsequent drop in blood pressure.

D-tubocurarine, one of the first neuromuscular blockers used clinically, can produce significant cardiovascular effects, including hypotension. This occurs because it not only blocks the neuromuscular junction but can also affect pre-and post-ganglionic autonomic transmission, leading to vasodilation. Metocurine, similarly, also has the potential to induce ganglionic blockade and therefore can result in hypotension.

In contrast, the other options consist of neuromuscular blockers that have a more selective action on neuromuscular transmission without significantly interfering with autonomic ganglia functions. For example, Vecuronium and Rocuronium primarily act at the neuromuscular junction with a lower incidence of hypotension. Pancuronium and Succinylch